Suppression of the Antigen-Stimulated RBL-2H3 Mast Cell Activation by Artekeiskeanol A

Abstract

Effects of artekeiskeanol A, a newly isolated coumarin derivative from Artemisa keiskeana Miq. (Compositae), the extract of which is used for treatment of rheumatoid arthritis as a folk medicine, on the antigen-induced activation of RBL-2H3 cells were examined. RBL-2H3 cells were sensitized with dinitrophenol (DNP)-specific IgE, and then stimulated with the antigen DNP-conjugated human serum albumin (DNP‐HSA). Artekeiskeanol A at 10 to 100 µM inhibited the antigen-induced degranulation in a concentration-dependent manner, the IC₅₀ value being 38.0 ± 0.2 µM. Degranulation induced by thapsigargin or A23187 also was inhibited by artekeiskeanol A at 10 to 100 µM. The antigen-induced increase in the levels of mRNA for tumor necrosis factor (TNF)-α and interleukin (IL)-13 and phosphorylations of Akt, p38 mitogen-activated protein kinase (MAPK), c-Jun N-terminal kinase (JNK) and p44/42 MAPK were also suppressed by artekeiskeanol A. Our findings suggested that the effectiveness of the extract of A. keiskeana might partly be due to the inhibition of mast cell activation by artekeiskeanol A.

Key words

Artemisia keiskeana Miq. - Compositae - artekeiskeanol A - RBL‐2H3 cells - degranulation - TNF‐α - IL‐13

References

• 1 Shanghai Scientific and Technologic Publisher and Shougakukan .The dictionary of Chinese drugs, Vol. 1. Tokyo; Shougakukan 1985: 19
• 2 Kwak J H, Lee K B, Schmitz F J. Four new coumarin derivatives from Artemisia keiskeana.  J Nat Prod Med. 2001;  64 1081-1083
• 3 Williams C M, Galli S J. The diverse potential effector and immunoregulatory roles of mast cells in allergic disease.  J Allergy Clin Immunol. 2000;  105 847-859
• 4 Hirasawa N, Santini F, Beaven M A. Activation of the mitogen-activated protein kinase/cytosolic phospholipase A₂ pathway in a rat mast cell line. Indication of different pathways for release of arachidonic acid and secretory granules.  J Immunol. 1995;  154 5395-5401
• 5 Hirasawa N, Sato Y, Fujita Y, Ohuchi K. Involvement of a phosphatidylinositol 3-kinase-p38 mitogen activated protein kinase pathway in antigen-induced IL‐4 production in mast cells.  Biochim Biophys Acta. 2000;  1456 45-55
• 6 Hirasawa N, Izumi S, Linwong W, Ohuchi K. Inhibition by dexamethasone of interleukin 13 production via glucocorticoid receptor-mediated inhibition of c-Jun phosphorylation.  FEBS Lett. 2003;  554 489-493
• 7 Bridges A J, Malone D G, Jicinsky J, Chen M, Ory P, Engber W, Graziano F M. Human synovial mast cell involvement in rheumatoid arthritis and osteoarthritis. Relationship to disease type, clinical activity, and antirheumatic therapy.  Arthritis Rheum. 1991;  34 1116-1124
• 8 Kobayashi Y, Okunishi H. Mast cells as a target of rheumatoid arthritis treatment.  Jpn J Pharmacol. 2002;  90 7-11
• 9 Lee D M, Friend D S, Gurish M F, Benoist C, Mathis D, Brenner M B. Mast cells: a cellular link between autoantibodies and inflammatory arthritis.  Science. 2002;  297 1689-1692
• 10 Eklund K K. Mast cells in the pathogenesis of rheumatic diseases and as potential targets for anti-rheumatic therapy.  Immunol Rev. 2007;  217 38-52
• 11 Hirasawa N, Sato Y, Fujita Y, Mue S, Ohuchi K. Inhibition by dexamethasone of mitogen-induced c-Jun N-terminal kinase activation in rat basophilic leukemia cells.  J Immunol. 1998;  161 4939-4943
• 12 Huber M, Hughes M R, Krystal G. Thapsigargin-induced degranulation of mast cells is dependent on transient activation of phosphatidylinositol-3 kinase.  J Immunol. 2000;  165 124-133
• 13 Zhang G, Baumgartner R A, Yamada K, Beaven M A. Mitogen-activated protein (MAP) kinase regulates production of tumor necrosis factor-α and release of arachidonic acid in mast cells. Indications of communication between p 38 and p 42 MAP kinases.  J Biol Chem. 1997;  272 13397-13402
• 14 Beutler B, Cerami A. The biology of cachectin/TNF-α – a primary mediator of the host response.  Annu Rev Immunol. 1989;  7 625-655
• 15 Wills-Karp M, Luyimbazi J, Xu X, Schofield B, Neben T Y, Karp C L, Donaldson D D. Interleukin-13: central mediator of allergic asthma.  Science. 1998;  282 2258-2261
• 16 Gon Y, Nunomura S, Ra C. Common and distinct signalling cascades in the production of tumour necrosis factor-alpha and interleukin-13 induced by lipopolysaccharide in RBL‐2H3 cells.  Clin Exp Allergy. 2005;  35 635-642
• 17 Ryu S Y, Kou N Y, Choi H S, Ryu H, Kim T S, Kim K M. Cnidicin, a coumarin, from the root of Angelica koreana, inhibits the degranulation of mast cell and the NO generation in RAW 264.7 cells.  Planta Med. 2001;  67 172-174
• 18 Kishiro S, Nunomura S, Nagai H, Akihisa T, Ra C. Selinidin suppresses IgE-mediated mast cell activation by inhibiting multiple steps of FcεRI signaling.  Biol Pharm Bull. 2008;  31 442-448
• 19 Watanabe J, Shinmoto H, Tsushida T. Coumarin and flavone derivatives from estragon and thyme as inhibitors of chemical mediator release from RBL‐2H3 cells.  Biosci Biotechnol Biochem. 2005;  69 1-6
• 20 Moon P D, Lee B H, Jeong H J, An H J, Park S J, Kim H R, Ko S G, Um J Y, Hong S H, Kim H M. Use of scopoletin to inhibit the production of inflammatory cytokines through inhibition of the IkappaB/NF-kappaB signal cascade in the human mast cell line HMC‐1.  Eur J Pharmacol. 2007;  555 218-225
• 21 Martin U, Roemer D. Ketotifen: a histamine release inhibitor.  Monogr Allergy. 1977;  12 145-149
• 22 Fischer B, Schmutzler W. Inhibition by azelastine of the immunologically induced histamine release from isolated guinea pig mast cells.  Arzneimittelforschung. 1981;  31 1193-1195